Through integrated multi-omics analysis and experimental validation, six genes, LIMS2, IRAK3, STX2, IL11RA, KCNMB1, and PDLIM7, were selected as potential immune-related biomarkers for bladder cancer, providing promising biomarkers and therapeutic targets for personalized treatment. Here, PDLIM7 is linked to urinary bladder cancer.